STOCK TITAN

Theralase Technologies Inc. - TLTFF STOCK NEWS

Welcome to our dedicated news page for Theralase Technologies (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theralase Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theralase Technologies's position in the market.

Rhea-AI Summary
Theralase Technologies has been granted a Clinical Trial Application Amendment by Health Canada for the optimization of the Phase II Non-Muscle Invasive Bladder Cancer clinical study. The optimization includes post-study monitoring of response, optional maintenance treatments, and central pathology laboratory review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
clinical trial
-
Rhea-AI Summary
Theralase Technologies files US patent for combining immunotherapy drugs with its PDC technology for increased cancer destruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
Rhea-AI Summary
Theralase completes preclinical toxicology analysis of Rutherrin for GBM, demonstrating safe administration and effectiveness in destroying tumor cells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
News
Rhea-AI Summary
Theralase® Technologies Inc. grants 360,000 stock options to directors and employees at $CAN 0.25 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
-
Rhea-AI Summary
Theralase Technologies Inc. closes a non-brokered private placement offering of units, raising approximately $460,000. The proceeds will be used for the advancement of a clinical study and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Theralase Technologies Inc. releases 2Q2023 financial statements. Revenue decreased 23% YoY. Gross margin decreased to 47% from 51% due to increased material costs. Selling expenses decreased 12%. Administrative expenses increased 37%. Net loss decreased 13%. Leadership change with Roger DuMoulin-White appointed as President and CEO. Theralase named to TSXV Venture 50. Completed non-brokered private placement. Extended expiry date of share purchase warrants. Working towards Break Through Designation for Study II. Preliminary clinical data shows positive response rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Theralase Technologies Inc.

OTC:TLTFF

TLTFF Rankings

TLTFF Stock Data

29.09M
211.97M
8.14%
0%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Canada
East York